Gyre Therapeutics to Merge with Cullgen

Gyre Therapeutics, Inc. entered into an agreement and plan of merger and reorganization with Helix Merger Sub Corp. and Cullgen Inc., dated March 2, 2026. The filing describes a merger structure with customary provisions for closing and effective time.

The agreement includes conversion of company equity securities and surrender of Cullgen capital stock, along with conditions precedent such as regulatory approvals, lock-up agreements, and other closing deliverables. It also covers intended tax treatment and appraisal rights.